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Administration of protein 
C concentrates in patients 
without congenital deficit: 
a systematic review of 
the literature
ABSTRACT
Endogenous protein C levels are frequently decreased in septic patients, probably due to increased conversion to activated 
protein C. Protein C levels inversely correlate with morbidity and mortality of septic patients regardless of age, infecting 
microorganisms, presence of shock, disseminated intravascular coagulation, degree of hypercoagulation, or severity of 
illness. Taken together, these considerations suggest a strong correlation between protein C pathways and survival from 
severe sepsis/septic shock, and reinforce the rationale for the attempts to normalize plasma activity of protein C to improve 
survival, hamper coagulopathy, and modulate inflammation. We therefore conducted a systematic review of all manuscripts 
describing protein C concentrates administration in adult and pediatric populations. We identified 28 studies, for a total of 
340 patients, 70 of whom died (20.6%). Septic patients were the most represented in this review of case reports and case 
series. In the majority of these patients sepsis was associated with meningitis, purpura fulminans or disseminated intravas-
cular coagulation. No bleeding complications related to the study drug were reported and most studies underlined norma-
lization of inflammatory markers and of coagulation abnormalities. We conclude that protein C concentrate is an attractive 
option in septic patients (especially those with meningitis, purpura fulminans, or disseminated intravascular coagulation) 
and that its cost-benefit ratio must be studied with a large multicenter randomized control trial, possibly including also high
risk patients with septic shock and multiple organ failure.
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Introduction
Sepsis is a highly complex process 
triggered by the release of numerous 
mediators that activate various defense 
systems, including the coagulation path-
way. Severe sepsis and septic shock 
are life-threatening medical emergen-
cies and are among the most significant 
challenges in critical care. Low endoge-
nous protein C (PC) levels are related to 
poor prognosis in patients with sepsis. 
(1) If low circulating PC levels could be 
restored to normal ones by infusion of 
exogenous PC, morbidity and mortality 
from sepsis might be reduced.
PC is a vitamin K-dependent serine 
protease produced by the liver, present 
in the blood as a zymogen activated by 
thrombomodulin, a complex of throm-
bin and endothelial thrombin receptor, 
situated on the membrane of endothe-
lial cells. Activated protein C (APC) 
exerts an anticoagulant effect and has 
anti-inflammatory and pro-fibrinolytic 
properties, preventing and reversing 
microvascular thrombus formation. (2)
Survival Sepsis Campaign Guidelines 
recommend treatment strategies such 
as early-goal directed therapy and 
the use of recombinant human APC 
(rhAPC). (3) Recently, the PROWESS 
SHOCK trial did not confirm the benefits 
of drotrecogin alfa (rhAPC), therefore 
the drug was withdrawn from the mar-
ket because of limited efficacy and the 
presence of side effects (bleeding).
Protein C concentrates (PCc) admini-
stration might be a useful alternative. (4) 
The safety and efficacy of intravenous 
or subcutaneous PCc for long-term 
prophylaxis in congenital PC deficiency 
is established since the year 1991. (5)
Few authors have tested the utility of 
PCc in young patients with purpura 
fulminans and/or meningitis and few 
reports exist on the use of PCc as an 
alternative treatment to rhAPC in adult 
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patients affected by sepsis or septic 
shock, in which rhAPC was contraindi-
cated by a high risk of bleeding.
We previously reviewed (6-8) the pub-
lished experience with PCc in 66 adults 
(6-14) and 118 children (12-25) without 
congenital defects. Considering the 
market withdrawal of rhAPC, the recent 
publication of further case series (26-
29) and the presence of reports (30-33) 
that were not identified in the previous 
reviews, we decided to update the sys-
tematic review and concisely summa-
rize the overall results.
Materials and methods
Search Strategy
BioMedCentral, PubMed, Embase and 
the Cochrane Central Register of Clini-
cal Trials were searched for pertinent 
studies (updated October 1st, 2012) by 
three investigators. The search includ-
ed the following terms: “protein C con-
centrate” or “protein C zymogen” or 
“Ceprotin”. Further searches involved 
conference proceedings from pertinent 
congresses. The references of retrieved 
articles were carefully checked. No lan-
guage restriction was enforced.
Study Selection
The search included the following terms: 
“protein C concentrate” or “protein C 
zymogen” or “Ceprotin”. Identified cita-
tions were assessed on the basis of the 
title and abstract by two investigators; 
disagreement was solved by consensus, 
with the supervision of a third investi-
gator. Potentially eligible studies were 
retrieved in full. Relevant studies were 
included in this systematic review of 
whether they met the following inclusion 
criteria: a) administration of PCc; b) study 
performed in adult or pediatric patients; 
c) excluding congenital PCc deficiency. 
Data Abstraction and Study Charac-
teristics
First author, year of publication, study 
design, number of patients, patient 
population, clinical setting, mortality, 
bleeding and number of amputations 
were independently extracted by two 
investigators.
Results
The systematic search initially identified 
a total of 6.335 titles (figure 1). Excluding 
4.758 non-pertinent titles, we retrieved 
in complete form and assessed 1.577 
studies according to the selection cri-
teria. Excluding 1.548 non-pertinent 
abstracts, and 3 (34-36) were excluded 
because the data were already pub-
lished in previous manuscripts, a total 
of 28 studies was finally selected, all of 
which described the administration of 
PCc in adult and pediatric populations 
without congenital deficits. The details of 
the 28 studies are reported in table 1. 
A total of 340 patients (232 children 
and 108 adults) was included and the 
overall mortality rate was of 20,6% (70 
patients). Only two studies were ran-
domized (20,28) while the others were 
case reports or case series, the largest 
study reporting 94 pediatric patients 
with purpura fulminans. (29) The stud-
ies were published between 1993 and 
2012, including mainly septic patients 
(94%). Sepsis was associated with 
meningitis, purpura fulminans, and dis-
seminated intravascular coagulation in 
most cases. 
All papers but one (29) reported nor-
malization of inflammatory markers 
and/or of coagulation abnormalities 
and/or improved outcome.
In 233 patients with purpura fulmin-
ans and/or meningitis, 26 amputations 
were described (11%). One mild aller-
gic reaction was reported as related to 
the study drug. No other adverse event 
related to PCc was reported among 
340 patients. 
Bleeding was reported as a complica-
tion only in two papers, (20,29) but the 
authors specified that it was not related 
to PCc administration. A randomized 
study performed in children described 
a mild gastrointestinal hemorrhage 
occurred in a patient who had severe 
disseminated intravascular coagula-
tion (DIC) and died of septic shock 
one day later. (20) Veldman in his case 
series described two cases of bleed-
ing: one patient developed epistaxis 
six hours after PCc administration, the 
other developed hemorrhage from the 
throat and the nose immediately after 
a difficult endotracheal intubation; both 
patients received the next dose of PCc 
without complications. (29)
Discussion
Protein C concentrates administration 
has been safely reported in more than 
300 patients without congenital PC 
deficiency. Most septic patients with or 
without meningitis had a normalization 
of laboratory findings after PCc adminis-
tration. When authors used a severity-of-
disease classification system, baseline 
Figure 1. Flow chart on the selection of the papers that describe the use of 
Protein C concentrates in patients without Protein C deficiency.
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Table 1. Summary of all published papers reporting on patients receiving protein C concentrates.
Author Setting Patients Deaths Amputations Predicted survival %
Crivellari M Sepsis/ septic shock 9 1 Non reported SAPS II: 32%
Landoni G Sepsis/ septic shock 2 0 Non reported
Baratto F Sepsis/ septic shock 20 7 Non reported SAPS II: 41%
Tuttolomondo A Sepsis/ septic shock 2 1 Non reported APACHE: 21%
Pettenazzo A Sepsis/ septic shock 8 2 0 PRISM: 56%
Silvani P Sepsis/ septic shock 11 3 Non reported
De Carolis MP Sepsis/ septic shock 1 0 Non reported
Betrosian AP Sepsis/ septic shock 3 0 Non reported
Behrendt J Sepsis/ septic shock 4 0 Non reported
Morelli A Sepsis/ septic shock 18 0 0
Ettingshausen CE Meningococcal sepsis 8 2 1
Clarke RC Meningococcal sepsis 1 0 Non reported
Leclerc F Meningococcal sepsis 1 0 1
Smith OP Meningococcal sepsis 12 0 2
GMSPS: 20%
PRISM: 43%
Lignell A Meningococcal sepsis 1 0 Non reported
Kreuz W Meningococcal purpura 7 2 1
White B Meningococcal purpura 36 3 4 GMSPS: 50%
Fourrier F Meningococcal purpura 15 9 3 PRISM: 31%
Vaccarella G Meningococcal purpura 1 0 0
Gerson WT Meningococcal purpura 1 0 1
Rivard GE Meningococcal purpura 4 0 2
Ruffini E Purpura fulminans 4 0 Non reported
De Kleijn ED Purpura fulminans 30 5 3 PRISM: 60%
Schellongowski P Purpura fulminans 8 2 2 SAPS II: 79%
Veldman A Purpura fulminans 94 21 5
Rintala E Purpura fulminans 12 5 3
Makris PE DIC 8 2 Non reported
Malato A DIC 19 5 Non reported
APACHE, Acute Physiology and Chronic Health Evaluation; DIC, disseminated intravascular coagulation; GMSPS, Glasgow Meningococcal
Septicaemia Prognostic Score; PRISM, Pediatric RIsk of Mortality; SAPS II, Simplified Acute Physiology Score.
scores generally indicated an expected 
mortality (21-60%) higher than the overall 
observed mortality (20.6%). All but three 
studies (13,32,33) were of poor quality 
(abstract) and two thirds of the popula-
tion was represented by children.
During severe sepsis, there is a reduc-
tion in PC concentration; PC correlates 
with increased morbidity and mortality. 
(1) Furthermore, in neonates PC levels 
reach the lower limit of normal adult 
levels (60-70%) around 6-12 months 
of age, (37) thereby increasing the risk 
of coagulopathy in the pediatric septic 
population. Recombinant human APC 
was always contraindicated in children 
and therefore majority of the manu-
scripts of PCc in the literature concerns 
the pediatric population. 
The published reports can be aggre-
gated into three main groups: a) sepsis 
and septic shock (12 studies with 80 
patients) b) purpura fulminans and/or 
meningitis (14 studies with 233 patients); 
c) DIC (2 studies with 27 patients).
A total of 12 studies (including 26 chil-
dren and 54 adults) described sepsis or 
septic shock patients treated with PCc: 
14 patients died; 5 children (19% mor-
tality) and 9 adults (17% mortality). The 
largest case series about PCc in sepsis 
has been published by Baratto et al. (7) 
They described the efficacy and safety 
of PCc to restore physiological values 
in 20 adult patients with severe sepsis 
or septic shock having clinical con-
traindications to treatment with rhAPC. 
Crivellari et al. (6) described their expe-
rience with the use of PCc in 9 adult 
patients with sepsis induced double 
organ failure after cardiac surgery. A 
pilot study (28) has reported the pre-
liminary findings on the effect of PCc 
on microcirculatory blood flow in adult 
septic shock patients.
Protein C concentrates administrations 
in patients with purpura fulminans and/
or meningitis were described in 14 stud-
ies for a total of 233 patients (only 28 of 
them adults). Meningococcemia is the 
major infective cause of purpura ful-
minans, a devastating complication of 
uncontrolled systemic inflammation. It 
is characterized by thrombocytopenia, 
petechiae, and ecchymoses together 
with disseminated thrombosis of small 
vessels, resulting in tissue hypoperfu-
sion, imminent peripheral gangrenes, 
and is associated with high incidence 
of amputations, skin grafts and death. 
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Almost all these reports described 
a sudden improvement in the clinical 
picture with the use of PCc in patients 
with purpura. The largest study in pur-
pura fulminans patients was performed 
in a pediatric population of 94 children by 
Veldman. (29) This retrospective multi-
center study showed that only few pedi-
atric patients under PC treatment needed 
dermatoplasty and/or amputations, com-
pared to historical controls. Apart from 
epistaxis (not related to the study drug), 
no bleeding was observed. A random-
ized phase 2, dose-finding study, was 
performed on 40 pediatric patients (30 
receiving PCc). This study showed a pos-
itive effect on sepsis induced coagulation 
abnormalities, but was not powered to 
show an effect on mortality rate. (20)
The less studied field was DIC. It is 
known that a pathogenetic mechanism 
of DIC is the reduction of protein C. In 
septic patients with DIC, substitution 
therapy with recombinant rhAPC has 
been proven to be effective, but with an 
increase in bleeding. In 2003 Makris and 
al. (13) treated 8 patients affected by 
overt DIC with PCc. Malato et al. (26) in 
2011 described for the first time the role 
of PCc in 19 adult cancer patients with 
overt DIC. While non overt chronic DIC is 
quite common in cancer patients, there 
are no reliable data regarding the inci-
dence and management of overt DIC. 
Malato et al. demonstrated the feasibility 
of PCc therapy for normalizing labora-
tory values and ameliorating the DIC 
score without bleeding or thrombosis.
Limitations
The main limitation of this systematic 
review is the poor quality of the included 
studies: all but two are non-randomized 
control trials (RTC).
Conclusions
Protein C zymogen caused one mild 
allergic reaction and no bleeding in 340 
patients with sepsis, purpura fulminans or 
DIC. Purpura fulminans in children is the 
most validated setting for the use of PCc 
in patients without congenital PC deficits, 
even if there is no randomized evidence 
to support survival benefits. Adult septic 
patients have a normalization of labora-
tory findings and a less than predicted 
mortality when receiving PCc, but case 
match and RCTs are still missing. 
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